Icahn to pick 3 for Biogen board
- Share via
Billionaire investor Carl Icahn said he would nominate three people to Biogen Idec Inc.’s board and criticized the company’s earlier attempt to find a buyer as “flawed.”
Biogen refused to let bidders talk to Irish drug maker Elan Corp., its partner in the multiple sclerosis treatment Tysabri, Icahn said in a regulatory filing. Biogen’s sale process also included a confidentiality agreement “so restrictive” that it prevented potential acquirers from bidding, he said.
The company fell 79 cents to $58.13.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
